Coronavirus: COVID-19 Total Cases: 32476713
Total Deaths: 987775 Total Recovered: 22378686

Coronavirus (COVID-19) Clinical Trials.

COVID-evidence is a constantly refreshed database of the overall accessible proof on intercessions for COVID-19. We give data about overall arranged, progressing, and finished preliminaries on any intercession to treat or forestall SARS-CoV-2-diseases. We consolidate programmed search procedures with master manual extraction of key preliminary qualities acted in copy. We work together with https://covid-evidence.org/.

Facebook, Twitter, and YouTube censor Capitol Hill Press Conference on massive Corona disinformation

Facebook has removed a video posted earlier today by Breitbart News, the world's highest-performing Facebook post on Monday afternoon, from a press conference in DC held by the group of America's Frontline Doctors organized and sponsored by the Tea Party Patriots. At the press conference, Rep. Ralph Norman (R-SC) and primary care physicians present who provided their views and opinions on coronavirus and the medical response to the pandemic. YouTube (owned by Google) and Twitter subsequently also removed images from the press conference. We don't even need to mention that it is an alternative Corona story than the irrational official story. There were times when only a message like this would win the majority and show what's going on here. Man evolves. Also in knowledge. However? 2020? The video has seen more than 17 million views during the eight hours that it has been hosted on Facebook, with more than 185,000 simultaneous viewers. Thanks to an attentive viewer and the luck that we saw the mail in time among the dozens of other mails, we were able to get the video. We saved. Also put on YouTube, but then hidden. Immediately removed. Instant. Then use some server space and place it via our own player: Video player 00:00 43:00 The event, organized by the organization Americas Frontline Doctors, a group founded by Dr. Simone Gold, a board-certified physician and lawyer, and made up of physicians, came together to discuss what the group calls a “massive disinformation campaign” about the coronavirus. Norman also spoke at the event. "If Americans continue to let so-called experts and media personalities take over, the great American experiment of a constitutional republic with representative democracy will end," the event's information page said. The event was organized and sponsored by the Tea Party Patriots. .
Jul 29, 2020, 9:35 pm
source: Breitbart News

The latest relevant trials regarding Corona virus (COVID-19)


Start date End date Status Country Participants enrolled Intervention name Title Source
2020-01-01 2021-01-01 recruiting China 120 Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days; PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion; Optimization of treatment and diagnosis plan for critically ill patients ICTRP
2020-01-01 2021-12-01 recruiting China 45 B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy; Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2020-12-01 recruiting China 380 Arbidol tablets + basic treatment Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2020-04-01 recruiting China 90 Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization; Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2020-02-01 recruiting China 300 experimental group 1:Hydroxychloroquine 0.1 oral 2/ day; experimental group 2:Hydroxychloroquine 0.2 oral 2/ day; Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2022-12-01 recruiting China 63 experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations; Experimental Group B1:Artificial liver therapy+conventional treatment. Experimental Group B2: Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment. Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-01-01 2020-05-01 not yet recruiting China 20 Suramin( IV.) A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2020-12-01 not yet recruiting China 400 Xuebijing Injiection A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-01-01 2020-03-01 recruiting China 120 experimental group:mesenchymal stem cells; Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19) ICTRP
2020-01-18 unknown completed China 199 lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day plus standard of care for 14 days A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. PubMed
2020-01-20 unknown recruiting China 3,030 Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment; Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study ICTRP
2020-01-20 2021-01-20 recruiting China 150 Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days. Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days. Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial clinicaltrials.gov
2020-01-27 unknown recruiting China 20 Conventional treatment plus mesenchymal stem cells (MSCs) Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6) Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus clinicaltrials.gov
2020-01-30 2020-08-31 recruiting China 30 Darunavir and cobicistat one tablet per day for 5 days in addition to conventional treatments Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV clinicaltrials.gov
2020-02-01 2022-02-01 recruiting China 20 standardized comprehensive treatment combined with convalescent plasma treatment; Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study ICTRP
2020-02-01 2020-12-01 recruiting China 30 Integrated Traditional Chinese and Western Medicine Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 600 TCM Group:herbal medicine and conventional treatment; QFPD decoction group:QFPD decoction and conventional treatment; SFJD capsuale group:SFJD capsuale and conventional treatment; Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2021-06-01 recruiting China 100 TCM based on symptomatic treatment Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-12-01 recruiting China 40 Polyinosinic-Polycytidylic Acid Injection and conventional therapy A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-12-01 recruiting China 90 General patients treated with normal treatment( Normal Treatment) General patients experimental group(Normal Treatment plus Sodium Aescinate for Injection) Severe patients experimental group(Normal Treatment plus Sodium Aescinate for Injection) A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 recruiting China 100 Case series:Treated with conventional treatment combined with Chloroquine Phosphate; A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) ICTRP
2020-02-01 2020-07-01 recruiting China 40 Conventional standardized treatment and vMIP atomized inhalation; Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial ICTRP
2020-02-01 2020-04-01 not yet recruiting China 100 Standard treatment and methylprednisolone for injection A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-06-01 not yet recruiting China 300 Truncated Torsion' Formula and Routine treatment of Western A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy ICTRP
2020-02-01 2021-02-01 recruiting China 100 conventional treatment combined with Chloroquine Phosphate. A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) ICTRP
2020-02-01 2021-12-01 recruiting China 60 Reduning injection combined with basic western medical therapies An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 110 honeysuckle decoction; A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection ICTRP
2020-02-01 2020-08-01 recruiting China 400 Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population ICTRP
2020-02-01 2021-04-01 not yet recruiting China 30 conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group; Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial ICTRP
2020-02-01 2021-12-01 not yet recruiting China 90 experimental group:Traditional Chinese Medicine+psychological intervention; Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period ICTRP
2020-02-01 2021-12-01 not yet recruiting China 100 TCM decoctions+basic western medical therapies Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial ICTRP
2020-02-01 2020-07-01 recruiting China 20 Chloroquine; A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 recruiting China 328 conventional standardized treatment and Lopinavir-Ritonavir A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-10-01 recruiting China 120 Western medicine basic treatment combined with traditional Chinese medicine; Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 not yet recruiting China 72 Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended. A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 188 conventional therapy+tocilizumab; A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 408 TCM and general treatment Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine ICTRP
2020-02-01 2020-08-01 recruiting China 42 Combined Treatment of Chinese medicine and western medicine Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial ICTRP
2020-02-01 2022-02-01 recruiting China 238 Xiyanping injection; Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 60 Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment; A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate ICTRP
2020-02-01 2020-04-01 not yet recruiting China 60 umbilical cord mesenchymal stem cells Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration ICTRP
2020-02-01 2020-05-01 recruiting China 20 (Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 recruiting China 200 Traditional Chinese Medicine Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2021-08-01 recruiting China 440 Hydrogen-Oxygen Nebulizer; A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-06-01 not yet recruiting China 120 Traditional Chinese medicine soup; A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-09-01 recruiting China 172 doctors group:Psychological intervention; nurses group:Psychological intervention; Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study ICTRP
2020-02-01 2020-08-01 recruiting China 600 health education, follow-up condition management by team of family doctors, Chinese medicine treatment; Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population ICTRP
2020-02-01 2020-03-01 not yet recruiting China 60 Supportive psychotherapy; Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2022-02-01 recruiting China 180 Psychological Intervention Group:"Intelligent Psychosomatic Regulation System" Intervention; A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression ICTRP
2020-02-01 2021-04-01 recruiting China 30 conventional treatment combined with umbilical cord blood mononuclear cells group; Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial ICTRP
2020-02-01 2020-05-01 not yet recruiting China 30 Experimental group 1:current antiviral treatment+Baloxavir Marboxil tablets; Experimental group 2:current antiviral treatment+fabiravir tablets; A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy ICTRP
2020-02-01 2020-12-01 not yet recruiting China 205 mild-moderate chloroquine group:oral chloroquine phosphate; mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir; severe-chloroquine group :oral chloroquine phosphate A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 160 Conventional standardized treatment and ASC09/Ritonavir; A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-12-01 recruiting China 60 Group A:traditional Chinese medicine treatment; Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir; Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 30 Favipiravir; Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir ICTRP
2020-02-01 2020-05-01 recruiting China 200 Chinese medicine treatment combined with western medicine treatment; Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province ICTRP
2020-02-01 2020-06-01 not yet recruiting China 30 A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.; B: Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days. Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients ICTRP
2020-02-01 2021-12-01 not yet recruiting China 100 TCM decoctions+basic conventional therapy A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2021-12-01 not yet recruiting China 100 shadowboxing +conventional treatment; The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period ICTRP
2020-02-01 2020-06-01 recruiting China 132 TCM+Routine treatment of Western Medicine Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial ICTRP
2020-02-01 2021-12-01 not yet recruiting China 120 TCM standard decoctions+basic western medical therapies; Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 not yet recruiting China 40 PD-1 mAb + Standard treatment Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19) ICTRP
2020-02-01 2022-12-01 recruiting China 60 inhalate the mycobacterium vaccae for injection Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection ICTRP
2020-02-01 2020-12-01 recruiting China 60 mild ill patients:conventional treatment and ozonated autohemotherapy; severe/critical ill patients:conventional treatment and ozonated autohemotherapy; Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 recruiting China 60 Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment; Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial ICTRP
2020-02-01 2021-12-01 recruiting China 348 Xiyanping injection+ conventional treatment A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-03-01 recruiting China 120 Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment; Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-07-01 recruiting China 16 severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the even, subsequent subjects were given 100 mg Bid for 7 consecutive. Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-03-01 not yet recruiting China 400 Exercise prescription A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students ICTRP
2020-02-01 2020-05-01 not yet recruiting China 100 Anti-SARS-CoV-2 virus inactivated plasma A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 60 Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d. High-dose group: Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d. A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 unknown recruiting China 50 Ganovo / ritonavir group:Ganovo/ ritonavir oral; Pegasys group:Pegasys injection; Novaferon group:Novaferon intramuscular injection+Spray inhalation; Coriolus group:Coriolus oral An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19) ICTRP
2020-02-01 2020-07-01 not yet recruiting China 120 Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment; Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 60 Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC) Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 130 Humanistic care+routine regimen The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 180 experimental group with common NCP:conventional treatment combined with ozone therapy; experimental group with severe NCP:conventional treatment combined with ozone therapy; experimental group with critical NCP: conventional treatment combined with ozone therapy A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 60 ozonated autohemotherapy; A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 240 Basic treatment combined Triazavirin; The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial ICTRP
2020-02-01 2020-08-01 not yet recruiting China 60 Conventional treatent and adalimumab; A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-03-01 recruiting China 68 Experience group:conventional therapy and ALA A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 unknown not yet recruiting China 60 Severe Group:probiotics; A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 100 Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days; An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 100 Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ; An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-02-01 recruiting China 90 Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2022-02-01 recruiting China 20 Case series:mesenchymal stem cells therapy; The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 recruiting China 300 Experimental group:atic treatment medicines A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 not yet recruiting China 320 A1:Hydroxychloroquine, small dose; A2:Hydroxychloroquine, high dose; A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-07-01 recruiting China 60 Experience group:conventional therapy and Tranilast; Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 300 experimental group.:Recombinant Human Interferon a1b Eye Drops A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 80 Experimental group:Chloroquine Phosphate; Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 not yet recruiting China 60 Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform ICTRP
2020-02-01 unknown recruiting China 300 Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid; Experimental group2: Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial ICTRP
2020-02-01 2020-08-01 not yet recruiting China 80 Case series:rehabilitation and Lung eight-segment exercise Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic ICTRP
2020-02-01 unknown not yet recruiting China 340 Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.; A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2021-01-01 active, not recruiting China 300 Yin Hu Qing Wen Decoction plus standard western medicine Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19 clinicaltrials.gov
2020-02-01 2020-04-01 enrolling by invititation China 60 Bromhexine Hydrochloride Tablets plus Arbidol Hydrochloride Granules plus Recombinant Human Interferon α2b Spray Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) clinicaltrials.gov
2020-02-01 2020-05-01 recruiting China 400 Methylprednisolone Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails clinicaltrials.gov
2020-02-01 2020-09-01 recruiting China 10 UC-MSCs (Umbilical cord mesenchymal stem cell) 3.3 * 107 cell number / 50ml / bag, 3 bags each time, infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection clinicaltrials.gov
2020-02-01 2020-06-01 recruiting China 100 basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days) An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia clinicaltrials.gov
2020-02-01 2020-05-01 recruiting China 60 ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day; Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia clinicaltrials.gov
2020-02-01 unknown recruiting China 400 Abidol hydrochloride 0.2g once,3 times a day,2 weeks; Oseltamivir 75mg once,twice a day,2 weeks; Lopinavir/ritonavir 500mg once,twice a day,2 weeks An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia. clinicaltrials.gov
2020-02-01 2020-03-01 not yet recruiting China 230 The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection clinicaltrials.gov
2020-02-01 2020-12-01 recruiting China 20 10mg Meplazumab (Anti-CD147 Humanized) by intravenous infusion, every day for 2 days Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia clinicaltrials.gov
2020-02-01 2020-06-01 recruiting China 294 Pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection clinicaltrials.gov
2020-02-01 2020-06-01 recruiting China 160 Truncation and Torsion Formula and Routine treatment of Western Medicine A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy ICTRP
2020-02-01 2020-12-01 recruiting China 112 Chloroquine Phosphate Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study ICTRP
2020-02-01 2020-04-01 recruiting China 1,000 Integrated Traditional Chinese and Western Medicine Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2021-02-01 recruiting China 520 Carrimycin The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial ICTRP
2020-02-01 2021-02-01 recruiting China 60 Regulating intestinal flora and standard of care Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 140 (ordinary) Chinese and Western Medicine Group; (severe) Chinese and Western Medicine Group A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 100 Chinese medicine decoction Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 unknown recruiting China 180 Traditional Chinese medicine qingfei prescription treatment; Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 recruiting China 72 Conventional Treatment & Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day); Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 20 Oral administration of 5 tablets of 1mg Azvudine tablets daily; A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 recruiting China 80 Conventional treatment + take Ba-Bao-Dan Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network ICTRP
2020-02-01 2020-04-01 not yet recruiting China 40 Routine treatment + Babaodan 6 capsules, bid orally Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-08-01 recruiting China 16 Two groups:Different stem cell doses; Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-12-01 not yet recruiting China 100 DDarunavir/cobicistat DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD); Lopinavir/ritonavir LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD); A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 100 Routine treatment + plasma treatment Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-12-01 not yet recruiting China 300 Conventional treatment and Shenfu injection; Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial ICTRP
2020-02-01 2021-02-01 recruiting China 400 Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.; Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.; High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment. A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-04-01 recruiting China 10 Case series:Anti-2019-nCoV virus inactivated plasma; A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19) ICTRP
2020-02-01 2020-08-01 not yet recruiting China 200 Conventional treatment +acupressure+Liuzijue qigong; Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial ICTRP
2020-02-01 2020-06-01 not yet recruiting China 828 Oral antiviral oral solution (Xiangxue Pharmaceutical); Oral "Wu-Zhi-Fang-Guan-Fang" decoction; A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-07-01 not yet recruiting China 186 Conventional treatment plus Dao Yin; A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 not yet recruiting China 100 integrated Chinese and conventional medicine; Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province ICTRP
2020-02-01 2020-06-01 recruiting China 160 routine treatment and Kangbingdu granules; A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-06-01 recruiting China 160 experimental group:Routine treatment and Shenqi Fuzheng Injection; A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-02-01 2020-07-01 not yet recruiting China 480 Group 1:Traditional Chinese Medicine prescription No. 1 and 2; Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-01 2020-05-01 recruiting China 40 Experimental group:ultra short wave Electrotherapy A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-02-06 2020-02-25 recruiting China 30 hydroxychloroquine 400mg per day for 5 days + also take conventional treatments Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) clinicaltrials.gov
2020-02-07 2020-06-30 not yet recruiting China 160 ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection clinicaltrials.gov
2020-02-09 2020-03-01 recruiting China 10 Sildenafil citrate tablets 0.1g/day for 14 days A Pilot Study of Sildenafil in the Treatment of COVID-19 clinicaltrials.gov
2020-02-11 2020-02-29 recruiting China 78 hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day; Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial) ICTRP
2020-02-12 2020-04-10 recruiting China 308 Remdesivir (RDV) 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days. A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease. clinicaltrials.gov
2020-02-15 2023-07-31 recruiting China 100 Pathogen-specific artificial antigen presenting cells. The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine clinicaltrials.gov
2020-02-15 2020-12-31 recruiting China 136 Drug: N-acetylcysteine+ Fuzheng Huayu Tablet The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks. A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV clinicaltrials.gov
2020-02-15 2020-05-01 recruiting International 20 Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) clinicaltrials.gov
2020-02-16 2022-02-15 recruiting China 48 Human Umbilical Cord Mesenchymal Stem Cells (US-MSC) 4 times 0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7 Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia clinicaltrials.gov
2020-02-17 2020-03-19 completed China 11 Ganovo+ritonavir+/-Interferon nebulization Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days. An Open and Controlled Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus(2019-nCoV) Infection clinicaltrials.gov
2020-02-18 2020-04-30 not yet recruiting China 40 Thalidomide, 100mg/d,qn,for 14 days The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study clinicaltrials.gov
2020-02-20 unknown recruiting China 9 Case series:mesenchymal stem cells therapy; Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia (COVID-19): a single-center, prospective, open clinical study ICTRP
2020-02-20 unknown recruiting China 5,050 experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid; Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine ICTRP
2020-02-20 unknown recruiting China 2,020 group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy; A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study ICTRP
2020-02-20 2020-12-30 recruiting China 30 Natural killer cells: twice a week of NK cells (0.1-2*10E7 cells/kg body weight) Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus clinicaltrials.gov
2020-02-20 unknown recruiting China 25,252,525 Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food; Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence. ICTRP
2020-02-22 2020-07-01 recruiting China 30 Fingolimod 0.5 mg Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19) clinicaltrials.gov
2020-03-01 2020-03-16 completed France 36 Hydroxychloroquine sulfate 200 mg, three times per day during ten days Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. PubMed
2020-03-01 2020-06-01 not yet recruiting China 200 experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment; A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-03-01 2020-06-01 not yet recruiting China 200 Traditional Chinese medicine compound granules + western medicine symptomatic treatment A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-03-01 2020-09-01 not yet recruiting China 80 Conventional Treatment & Low Dose Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks) Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2020-03-01 2020-05-01 not yet recruiting China 200 Oral leflunomide A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2020-03-01 2021-12-01 not yet recruiting China 40 Iv injection of Wharton's Jelly mesenchymal stem cells (1×10^6/kg), cell suspension volume: 40ml; Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) ICTRP
2020-03-01 2020-11-01 not yet recruiting Italy 200 VivaDiag™ COVID-19 lgM/IgG Rapid Test Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19 clinicaltrials.gov
2020-03-01 2022-12-01 recruiting Italy 330 Tocilizumab Injection Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia clinicaltrials.gov
2020-03-01 2021-03-01 recruiting United States 400 Sarilumab high dose; Sarilumab low dose An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 clinicaltrials.gov
2020-03-01 2025-03-01 not yet recruiting Norway 202 Hydroxychloroquine Sulfate in addition to standard of care Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection clinicaltrials.gov
2020-03-01 2020-09-01 recruiting Jordan 5 Wharton's Jelly-Mesenchymal Stem Cells suspended in 25 ml of Saline solution containing 0.5% human serum Albumin Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells clinicaltrials.gov
2020-03-01 2023-03-01 not yet recruiting International 3,200 Remdesivir (200 mg intravenous loading dose then 100 mg once-daily intravenous maintenance dose up to a 10 days total course) plus standard of care; Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir every 12 h for 14 days) plus standard of care; Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir every 12 h for 14 days) plus Interferon ß1 (44 µg subcutaneously for a total of 3 doses in 6 days) plus standard of care. Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults clinicaltrials.gov
2020-03-01 2021-04-01 not yet recruiting United States 516 Losartan Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization clinicaltrials.gov
2020-03-01 2020-05-01 not yet recruiting China 10 Immunoglobulin of cured patients 0.2g/kg, ivdrip, once a day, for 3 day An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients clinicaltrials.gov
2020-03-01 2020-05-01 not yet recruiting Italy 30 Tocilizumab (RoActemra) single intravenous administration 8mg/Kg Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia clinicaltrials.gov
2020-03-01 2020-10-01 not yet recruiting China 80 Rehabilitation Lung Health Eight - Stage Exercise The Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19) ICTRP
2020-03-01 2020-09-30 not yet recruiting United States 2,000 Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study clinicaltrials.gov
2020-03-03 2020-06-21 recruiting United States 45 25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29. n=15 (4 sentinel, 11 non-sentinel). Intervention: Biological: mRNA-1273 Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults clinicaltrials.gov
2020-03-05 2021-03-01 enrolling by invititation China 60 Tetrandine 60 mg per day for 1 week Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19 clinicaltrials.gov
2020-03-05 2021-12-31 recruiting China 90 3 times of Mesenchymal Stem Cell (MSC)s (4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6. Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19) clinicaltrials.gov
2020-03-05 2020-07-30 not yet recruiting China 24 Dental pulp mesenchymal stem cells were injected intravenously Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells clinicaltrials.gov
2020-03-06 2020-05-01 recruiting International 400 continued standard of care therapy together with Remdesivir (RDV) 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 clinicaltrials.gov
2020-03-08 2020-05-01 recruiting China 150 Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days. Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.; Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study clinicaltrials.gov
2020-03-11 2020-05-01 recruiting Korea, Republic of 150 Lopinavir/ritonavir; Hydroxychloroquine Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) clinicaltrials.gov
2020-03-15 2020-10-31 not yet recruiting Thailand 80 Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19; Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19; Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19; Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19; Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19; Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19; Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19 A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Chloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Chloroquine in Moderate to Critically Ill COVID19 clinicaltrials.gov
2020-03-15 2020-05-01 recruiting International 600 Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4 and 5; Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment clinicaltrials.gov
2020-03-16 2021-04-01 not yet recruiting United States 200 Losartan; 25 mg daily; oral administration. Other Name: Cozaar Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization clinicaltrials.gov
2020-03-17 2020-06-30 recruiting China 140 Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multi-Centered Randomized Controlled Clinical Trial clinicaltrials.gov
2020-03-17 2020-04-21 recruiting International 3,000 Hydroxychloroquine 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial clinicaltrials.gov
2020-03-18 2020-06-15 recruiting Spain 3,040 darunavir 800 mg / cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4, 5, 6 and 7. Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4. Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) clinicaltrials.gov
2020-03-20 2021-03-30 not yet recruiting China 116 Yinhu Qingwen Granula is a kind of herbal granula made from "Yinhu Qingwen Decoction", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days. An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 clinicaltrials.gov
2020-03-20 unknown recruiting China 20 Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion i Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19) ICTRP
2020-03-20 unknown recruiting United Kingdom 500 Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient fo Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC) ICTRP
2020-03-21 2021-04-01 recruiting United States 240 Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient. Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial clinicaltrials.gov
2020-03-21 2021-03-22 recruiting United States 200 80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop. Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively. Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial. clinicaltrials.gov
2020-03-23 2022-03-23 recruiting French Guiana 450 Human biological samples and questionnaires Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana clinicaltrials.gov
2020-03-24 unknown recruiting Belgium 80 Inhaled sargramostim (125mcg twice daily for 5 days). Intravenous sargramostim (125mcg/m2 body surface area once daily) upon progression to ARDS and initiation of mechanical ventilator. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. clinicaltrials.gov
2020-03-25 2021-12-31 enrolling by invititation United States 10 cellular stromal vascular fraction Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection clinicaltrials.gov
2020-03-30 2020-12-31 recruiting United States 300 hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial clinicaltrials.gov
2020-03-30 2020-10-30 recruiting Australia 4,170 Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm). BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial clinicaltrials.gov
2020-03-31 2020-10-31 recruiting Netherlands 130 Best supportive Care (BSC) + IFX-1 A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia clinicaltrials.gov
2020-04-01 2021-03-01 not yet recruiting China 280 DAS181 SD group 4.5mg/day for 7 or 10 days; DAS181 HD group 9mg/day for 7 or 10 days.; DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.; DAS181 4.5mg/day or 9mg/day for 7 or 10 days A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection clinicaltrials.gov
2020-04-01 2020-06-01 not yet recruiting China 210 Favipiravir - on the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days. The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive clinicaltrials.gov
2020-04-01 2020-10-01 not yet recruiting United States 100 PUL-042 Inhalation Solution given by nebulization on study days 1, 3 and 6; A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection clinicaltrials.gov
2020-04-01 2021-04-01 not yet recruiting International 40,000 A loading dose of 10 mg base/ kg followed by 155 mg daily (in Asia: 250mg chloroquine phosphate salt; in Europe: 200mg of or hydroxychloroquine sulphate) will be taken for 3 months Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV) clinicaltrials.gov
2020-04-01 2020-12-01 not yet recruiting Canada 576 Medical Mask (known also as Surgical Mask). Medical Mask worn when providing care to patient with febrile respiratory illness Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial clinicaltrials.gov
2020-04-01 2020-09-01 not yet recruiting International 120 Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress clinicaltrials.gov
2020-04-01 2021-04-01 not yet recruiting Mexico 20 Convalescent Plasma from patients who recently recover from COVID-19 plus supportive standard care Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection clinicaltrials.gov
2020-04-01 2020-06-01 not yet recruiting Mexico 20 Ruxolitinib 10 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib clinicaltrials.gov
2020-04-01 2020-06-01 recruiting France 273 Chloroquine analog (GNS651) 200mg bid loading dose for 2 days then, 200 qd orally for 14 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day. ; Nivolumab 0.3mg/Kg, intravenously, single infusion at Day 1.; Chloroquine analog (GNS651) 200mg bid loading dose for 2 days then, 200 qd/day orally, per os, for 14 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.; Tocilizumab 400mg flat dose, intravenously, single infusion at Day 1. A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection clinicaltrials.gov
2020-04-01 2020-07-31 not yet recruiting United States 2,271 a single 1 g dose of oral azithromycin Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19 clinicaltrials.gov
2020-04-01 2020-05-20 not yet recruiting Spain 100 A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion. Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia clinicaltrials.gov
2020-04-01 2020-04-01 not yet recruiting United States 5 The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use. GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 clinicaltrials.gov
2020-04-01 2021-04-01 not yet recruiting Vietnam 250 chloroquine with a loading dose of 1200mg CQ phosphate base over the first 24 hours after randomization, followed by 300mg CQ phosphate base orally once daily for 9 days, in addition to standard of care therapy A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam clinicaltrials.gov
2020-04-02 unknown recruiting United States 510 hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course. Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease clinicaltrials.gov
2020-04-03 2020-10-03 recruiting Spain 440 hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial clinicaltrials.gov
2020-04-04 2020-07-01 recruiting United States 50 Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours. Second dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response. Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis clinicaltrials.gov
2020-04-05 2020-05-30 enrolling by invititation United States 82 twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy. Acceptance and Commitment Therapy Delivered by Automated Software Messaging clinicaltrials.gov
2020-04-06 2020-06-20 not yet recruiting Israel 40 Piclidenoson 2 mg every 12 hours orally added to standard of care Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial clinicaltrials.gov
2020-04-06 2020-10-30 not yet recruiting Canada 64 All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day. Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia clinicaltrials.gov
2020-04-06 2020-11-06 not yet recruiting Spain 800 Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months. Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection clinicaltrials.gov
2020-04-06 2020-07-01 recruiting United States 40 The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient. Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19 clinicaltrials.gov
2020-04-06 2021-01-01 recruiting United States 4,000 lopinavir/ritonavir 400mg/200mg mg po BID X 5-14 days depending on availablity; hydroxychloroquine sulfate 400 mg BID on Day 0 200 mg BID Days 1-4, days 1-13 if available; losartan 25 mg po QD X 5-14 days depending on availability Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) clinicaltrials.gov
2020-04-08 2021-04-01 not yet recruiting United States 400 hydroxychloroquine 400 mg twice a day for up to 14 days; hydroxychloroquine 600 mg twice a day for up to 14 days; hydroxychloroquine 600 mg once a day for 2 months The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) clinicaltrials.gov
2020-04-10 2020-06-30 not yet recruiting Spain 200 The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption. Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19 clinicaltrials.gov
2020-04-11 2020-11-30 not yet recruiting France 1,200 HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards; LPV/r 200/50 mg, 2 tablets twice daily Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial clinicaltrials.gov
2020-05-01 2022-05-01 not yet recruiting United States 230 CD24Fc, single dose at Day 1, 480mg, diluted to 100ml with normal saline, IV infusion in 60 minutes A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment clinicaltrials.gov
2021-01-20 unknown recruiting China 120 Case series:Integration of traditional Chinese and Western Medicine; Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2022-01-20 unknown recruiting China 0 Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19) ICTRP
2022-02-20 unknown recruiting China 3,030 Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment; Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial ICTRP
2023-02-20 unknown recruiting China 5,050 Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious); Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine ICTRP
2024-02-20 unknown recruiting China 400 Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical care ultrasound examination; The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2025-01-20 unknown recruiting China 363,636 arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b; Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia ICTRP
2025-02-20 unknown recruiting China 1,010 Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment; An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2025-02-20 unknown recruiting China 3,030 Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment; Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) ICTRP
2025-03-20 unknown recruiting United Kingdom 3,000
The trial will initially be two-arm, comparing COVID-19 swabbing plus standard care to COVID-19 swabbing plus hydroxychloroquine with usual care.

The trial will be implemented in the first instance in practices t
Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) ICTRP
2026-02-20 unknown recruiting China 2,020 Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ; Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19) ICTRP
2026-02-20 unknown recruiting China 1,515 A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin; Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection ICTRP
2027-02-20 unknown recruiting China 102,102 experimental group:TCM formula and general treatment based on "Diagnosis and Treatment Program for COVID-19" (trial version 6th);control group:general treatment based on "Diagnosis and Treatment Program for COVID-19" (trial version 6th); Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine ICTRP
2027-02-20 unknown recruiting China 4,848 Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN; A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2027-02-20 unknown recruiting Japan 50 oral administration of favipiravir A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19. ICTRP
2029-01-20 unknown recruiting China 2,424 Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kg·d for 3 days.;Control group:Without any glucocorticoid therapy; A study on treatment strategies of novel coronavirus pnueumonia patients ICTRP
2029-01-20 unknown recruiting China 11,501,150 Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water; Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19) ICTRP
2029-01-20 unknown recruiting China 303,030 Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / riton A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19) ICTRP
2029-02-20 unknown recruiting China 3,030 Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 da Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial ICTRP
2030-01-20 unknown recruiting China 1,000,010,000 Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention; Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population ICTRP
2031-01-20 unknown recruiting China 3,535 Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group: Routine treatment; Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial ICTRP
Loading